title: Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.
abstract: Activation and inactivation of protein C during the clinical course of disseminated intravascular coagulation (DIC) was studied in three patients by qualitative (Western blotting) and quantitative (ELISA) analysis and the intensity of procoagulant activity monitored by the measurement of thrombin and factor Xa antithrombin III complexes. In one patient, inhibitor complexes of APC with protein C inhibitor (PCI) and alpha 1-antitrypsin (alpha 1-AT) were observed and the latter predominated at presentation. Both disappeared during the development of remission but the loss of alpha 1-AT complexes preceded PCI complexes which on Western blotting appeared to increase in intensity prior to disappearance. The two other patients bled to death from uncontrollable haemorrhage. In both cases, APC/inhibitor complexes with alpha 2-macroglobulin (alpha 2-M) in addition to PCI and alpha 1-AT were detected and persisted until death. Although PCI appeared to be the primary inhibitor in all three cases, alpha 1-antitrypsin and particularly alpha 2-macroglobulin appeared to assume greater roles in the two fatal cases. These data are similar to previous findings in an experimental animal model of DIC that suggested that alpha 2-macroglobulin and alpha 1-antitrypsin become more important inhibitors of APC as the primary inhibitor PCI is consumed in the face of a sustained procoagulant challenge.
authors.affiliation: Department of Haematology, Royal Victoria Hospital Montreal, Quebec, Canada.
authors.forename: M F
authors.initials: MF
authors.lastname: Scully
authors.forename: C H
authors.initials: CH
authors.lastname: Toh
authors.forename: H
authors.initials: H
authors.lastname: Hoogendoorn
authors.forename: R P
authors.initials: RP
authors.lastname: Manuel
authors.forename: M E
authors.initials: ME
authors.lastname: Nesheim
authors.forename: S
authors.initials: S
authors.lastname: Solymoss
authors.forename: A R
authors.initials: AR
authors.lastname: Giles
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001780:Blood Coagulation Tests; D002543:Cerebral Hemorrhage / Q000097:blood; D004211:Disseminated Intravascular Coagulation / Q000097:blood*; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D015849:Plasminogen Inactivators / Q000378:metabolism*; D011183:Postoperative Complications / Q000097:blood; D011486:Protein C / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018046:Protein C Inhibitor; D011644:Puerperal Disorders / Q000097:blood; D000515:alpha 1-Antitrypsin / Q000378:metabolism*; D000511:alpha-Macroglobulins / Q000378:metabolism*
chemical_list: D015849:Plasminogen Inactivators; D011486:Protein C; D018046:Protein C Inhibitor; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases